Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Average serum TG level decreased significantly after treatment in the group A (P < 0.0001), but in the resistant group, no significant change was observed in TG serum level (P = 0.356) (Table 4).Changes in anthropometric, biochemical, lipid profiles, and liver function parameters before and three months after treatment to eradicate H. pylori infection based on response to treatmentVariables, mean ± S.D (Min-Max)Response to treatment (N = 164)Resistant to treatment (N = 35)P-value*Anthropometric parameters Weight, Kg Before treatment73.18 ± 14.67 (48 to 135)73.74 ± 15.53 (45 to 110)0.685 After treatment71.46 ± 12.86 (33 to 125)73.44 ± 15.10 (45 to 110)0.5000.011**0.568** BMI, Kg/m 2 Before treatment25.62 ± 4.33 (18.2 to 43)27.13 ± 6.32 (16.5 to 42.97)0.188 After treatment25.54 ± 4.41 (18.2 to 45)26.9 ± 6.16 (16.5 to 42.97)0.2360.074**0.172**Biochemical parameters Hb, g/dl Before treatment12.73 ± 2.05 (8.5 to 17.5)13.10 ± 1.96 (8.9 to 16.0)0.336 After treatment13.4 ± 3.39 (8.5 to 17.5)12.97 ± 2.03 (8.6 to 17)0.8460.086**0.083** PLT, µL 103 Before treatment295.37 ± 84.21 (121 to 584)284.48 ± 82.47 (150 to 468)0.507 After treatment292.05 ± 81.75(120 to 484)283.90 ± 73.85 (150 to 391)0.6070.937**0.016** MCV, fL Before treatment83.61 ± 5.00 (66 to 98)83.86 ± 5.12 (74 to 98)0.989 After treatment83.96 ± 5.51 (58 to 98)83.53 ± 4.79 (71 to 95)0.9340.935**0.278** FBS, mg/dl Before treatment96.17 ± 23.12 (63 to 302)97.14 ± 15.53 (68 to 141)0.455 After treatment94.22 ± 15.12 (61 to 170)97.60 ± 14.13 (71 to 140)0.3950.759**0.346** BUN, mmol/L Before treatment15.34 ± 6.06 (2.0 to 38.0)17.04 ± 5.94 (7.0 to 30)0.094 After treatment16.59 ± 8.70 (1.6 to 84)17.91 ± 6.47 (7.0 to 30)0.4270.073**0.782** Cr, mg/dL Before treatment1.77 ± 1.78 (0.2 to 8.0)1.56 ± 1.30 (0.6 to 6.0)0.733 After treatment1.76 ± 1.73 (0.2 to 8.0)1.51 ± 1.35 (0.6 to 6.5)0.8730.522**0.428** Calcium, mg/dL Before treatment8.61 ± 0.83 (5.7 to 10.5)9.01 ± 0.64 (7.20 to 9.80)0.061 After treatment8.79 ± (7.5 to 10.5)9.15 ± 0.57 (8.10 to 10.10)0.0380.549**0.634** TSH, mIU/L Before treatment2.62 ± 1.34 (0.4 to 8.5)2.29 ± 1.12 (0.3 to 5.50)0.591 After treatment2.47 ± 1.09 (0.6 to 6.1)2.25 ± 1.25 (0.3 to 5.75)0.4960.299**0.549** 25-OH-VitD, ng/mL Before treatment26.80 ± 27.34 (6.0 to 65.0)28.56 ± 13.48 (13 to 60)0.768 After treatment29.02 ± 9.84 (3.7 to 56.0)30.93 ± 12.76 (16 to 56)0.8940.210**0.057**Lipid profiles TC, mg/dL Before treatment163.85 ± 37.68 (77 to 275)175.14 ± 38.37 (91 to 265)0.137 After treatment166.37 ± 35.75 (80 to 289)173.51 ± 38.83 (115 to 279)0.3220.837**0.754** TG, mg/dL Before treatment155.65 ± 56.20 (56 to 253)152.09 ± 51.06 (96.5 to 253.5)0.313 After treatment150.94 ± 48.90 (39 to 271)150.26 ± 43.41 (85 to 280)0.472< 0.0001**0.468** HDL-C, mg/dL Before treatment39.58 ± 17.98 (18 to 131)44.41 ± 12.75 (23 to 80)0.013 After treatment40.85 ± 11.57 (18 to 97)45.35 ± 11.89 (27 to 74)0.0430.121**0.624** LDL-C, mg/dL Before treatment87.67 ± 29.81 (25 to 195)103.65 ± 35.51 (20 to 165)0.016 After treatment86.82 ± 28.71 (25 to 167)103.85 ± 35.75 (24 to 185)0.0270.457**0.449** VLDL-C, mg/dL Before treatment43.34 ± 12.94 (11 − 85)42.46 ± 17.71 (11 to 95)0.327 After treatment39.52 ± 10.27 (7 to 61)40.71 ± 15.9 (15 to 68)0.5490.265**0.116**Liver function parameters AST, U/L Before treatment27.02 ± 10.09 (12 to 68)26.80 ± 16.36 (9 to 90)0.174 After treatment28.10 ± 12.62 (12 to 99)26.46 ± 10.93 (10 to 71)0.3410.194**0.059** ALT, U/L Before treatment30.59 ± 12.65 (10 to 69)30.0 ± 16.96 (10 to 79)0.378 After treatment31.21 ± 12.74 (10 to 88)31.23 ± 13.36 (11 to 74)0.9450.502**0.096** ALP, IU/L Before treatment210.39 ± 80.92 (61 to 420)207.51 ± 68.63 (61 to 357)0.880 After treatment214.10 ± 72.42 (61 to 488)195.86 ± 64.51 (61 to 401)0.5540.804**0.026** Total bilirubin, mg/dL Before treatment0.97 ± 1.28 (0.1 to 14.0)0.81 ± 0.52 (0.2 to 2.50)0.898 After treatment0.94 ± 1.39 (0.1 to 6.0)0.83 ± 0.51 (0.2 to 2.5)0.4600.051**0.566** Direct bilirubin, mg/dL Before treatment0.95 ± 1.39 (0.1 to 14.0)0.436 After treatment0.37 ± 0.69 (0.1 to 6.0)0.25 ± 0.23 (0.1 to 1.10)0.24 ± 0.22 (0.1 to 1.10)0.6480.891**0.979**BMI Body mass index; Hb Hemoglobin; PLT Platelet count; MSV Mean corpuscular volume; FBS Fasting blood sugar; BUN Blood urea nitrogen; Cr Creatinine; TSH Thyroid-stimulating hormone; 25-OH-VitD 25-hydroxyvitamin D (25(OH)D); TC Total cholesterol; TG Triglyceride, HDL-C High-density lipoprotein cholesterol; LDL-C Low density lipoprotein cholesterol; VLDL-C Very low density lipoprotein cholesterol; AST Aspartate aminotransferase; ALT Alanine aminotransferase; ALP Alkaline phosphatase*Mann-Whitney U, **P-value, Wilcoxon test

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Case-control study.

Case-control study

Compares people with an outcome against people without it, examining exposures.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Effect of Helicobacter pylori eradication on metabolic profile: an international, multicenter, case-control study

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Effect of Helicobacter pylori eradication on metabolic profile: an international, multicenter, case-control study

Case-control study · BMC Gastroenterology · 2022

Original publication title

Effect of Helicobacter pylori eradication on metabolic profile: an international, multicenter, case-control study

Pezhman Alavinejad; Eskandar Hajiani; Abazar Parsi; Azam Satari; Mohammad Javad Rezaei; Morteza Nayebi; Ahmad Hormati; Omid Eslami; Mohammed Hussien Ahmed; Quang Trung Tran; Masoud Arshadzadeh; Siamak Baghaei; Samira Mohammadi; Seyed Jalal Hashemi; Alireza Sedaghat

© The Author(s) 2022

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

HP infection treatment in individuals without significant metabolic disorders does not affect metabolic parameters up to 3 months after eradication. HP eradication among subjects with several comorbidities mandates eradication protocol intensification to avoid treatment failure.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

As a gram-negative and microaerophilic bacterium, Helicobacter pylori (HP) is the main cause of chronic gastritis. Therefore, considering the high prevalence of HP infection worldwide, as well as the increasing prevalence of metabolic disorders, the present study aimed to investigate the relationship between HP infection eradication and metabolic profile.

Source: Background

Abstract: What methods does the paper describe?

This prospective case-control study was performed on patients with HP infection whom referred to 7 medical centers in 3 countries (Iran, Egypt, and Vietnam) in 2020 to 2021. The metabolic profile of all of the participants evaluated before starting of treatment for HP eradication and 3 months after the treatment. Then changes of metabolic profile compared between those with successful HP eradication (group A) and subjects who failed to eradicate (group B).

Source: Methods

Abstract: Results

Overall, 199 patients, including 93 male (46.7%) with the mean age of 44.5 years (18 to 93 years) included. Based on response to treatment, the participants allocate into group A (those who respond to HP eradication): 164 cases (82.42%); or group B as those who failed to achieve eradication (35 cases, 17.58%). Racially 86.9% of participants were Caucasian and 89% diagnosed as non-ulcer dyspepsia (NUD). The most prevalent comorbidity include hypertension (11.5%) and hyperlipidemia (10%) which were more prevalent in group B (P = 0.002).

 Three months after therapy, average weight of participants among those who achieved eradication (group A) decreased from 73.1 to 71.4 kg (P = 0.01), but in comparison with group B, was non-significant (P = 0.171). The BMI of patients before and after treatment did not show any significant differences. The biochemical parameters of patients before and after treatment were not significantly different regardless of treatment success (P > 0.05). The levels of total cholesterol and VLDL cholesterol after treatment were not significantly different from baseline values in two groups.

HDL and LDL cholesterol levels before and after treatment in the resistant group were significantly higher than the responding group. Average serum TG level decreased significantly after treatment in the group A (P < 0.0001), in contrast to the resistant group (P = 0.356). The liver transaminases (AST and ALT) before and after treatment were not significantly different between the two groups (P > 0.05). The results of logistic regression showed that the eradication of infection has no significant affect any of the metabolic profile parameters.

Source: Results

Abstract: Conclusion

HP infection treatment in individuals without significant metabolic disorders does not affect metabolic parameters up to 3 months after eradication. HP eradication among subjects with several comorbidities mandates eradication protocol intensification to avoid treatment failure.

Source: Conclusion
Authors’ abstract

Background

As a gram-negative and microaerophilic bacterium, Helicobacter pylori (HP) is the main cause of chronic gastritis. Therefore, considering the high prevalence of HP infection worldwide, as well as the increasing prevalence of metabolic disorders, the present study aimed to investigate the relationship between HP infection eradication and metabolic profile.

Methods

This prospective case-control study was performed on patients with HP infection whom referred to 7 medical centers in 3 countries (Iran, Egypt, and Vietnam) in 2020 to 2021. The metabolic profile of all of the participants evaluated before starting of treatment for HP eradication and 3 months after the treatment. Then changes of metabolic profile compared between those with successful HP eradication (group A) and subjects who failed to eradicate (group B).

Results

Overall, 199 patients, including 93 male (46.7%) with the mean age of 44.5 years (18 to 93 years) included. Based on response to treatment, the participants allocate into group A (those who respond to HP eradication): 164 cases (82.42%); or group B as those who failed to achieve eradication (35 cases, 17.58%). Racially 86.9% of participants were Caucasian and 89% diagnosed as non-ulcer dyspepsia (NUD). The most prevalent comorbidity include hypertension (11.5%) and hyperlipidemia (10%) which were more prevalent in group B (P = 0.002).

 Three months after therapy, average weight of participants among those who achieved eradication (group A) decreased from 73.1 to 71.4 kg (P = 0.01), but in comparison with group B, was non-significant (P = 0.171). The BMI of patients before and after treatment did not show any significant differences. The biochemical parameters of patients before and after treatment were not significantly different regardless of treatment success (P > 0.05). The levels of total cholesterol and VLDL cholesterol after treatment were not significantly different from baseline values in two groups.

HDL and LDL cholesterol levels before and after treatment in the resistant group were significantly higher than the responding group. Average serum TG level decreased significantly after treatment in the group A (P < 0.0001), in contrast to the resistant group (P = 0.356). The liver transaminases (AST and ALT) before and after treatment were not significantly different between the two groups (P > 0.05). The results of logistic regression showed that the eradication of infection has no significant affect any of the metabolic profile parameters.

Conclusion

HP infection treatment in individuals without significant metabolic disorders does not affect metabolic parameters up to 3 months after eradication. HP eradication among subjects with several comorbidities mandates eradication protocol intensification to avoid treatment failure.

Publication and source details

Original title: Effect of Helicobacter pylori eradication on metabolic profile: an international, multicenter, case-control study

Pezhman Alavinejad; Eskandar Hajiani; Abazar Parsi; Azam Satari; Mohammad Javad Rezaei; Morteza Nayebi; Ahmad Hormati; Omid Eslami; Mohammed Hussien Ahmed; Quang Trung Tran; Masoud Arshadzadeh; Siamak Baghaei; Samira Mohammadi; Seyed Jalal Hashemi; Alireza Sedaghat

BMC Gastroenterology · 2022

© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T21:40:14.521819+00:00

DOI: 10.1186/s12876-022-02604-3 · PMC9733255